Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
P. Kay Wagoner | M | 75 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 32 years |
Robert James Jakobs | M | 69 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 26 years |
André L. Lamotte | M | 75 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 32 years |
Richard G. Morrison | M | 87 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 20 years |
Douglas S. Krafte | M | 64 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 25 years |
Charlie Sanders | M | 91 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 27 years |
Dennis B. Gillings | M | 79 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 27 years |
Ruth McKernan | M | 66 |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | - |
Gregory C. Rigdon | M | - |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | 27 years |
Rebecca Dias | F | - |
Neusentis, Inc.
Neusentis, Inc. Pharmaceuticals: MajorHealth Technology Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 10 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William G. Roche
- Personal Network